Iva Barjaktarovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Iva Barjaktarovic has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Ljuba Vujanović
University of Novi Sad, Faculty of Medicine, Department of Dermatovenereology, Novi Sad, Serbia + University Clinical Center of Vojvodina, Clinic of Dermatovenereology Diseases, Novi Sad, Serbia
3 shared publications - Sanja Jakovljevic
University of Novi Sad, Faculty of Medicine, Department of Dermatovenereology, Novi Sad, Serbia + University Clinical Center of Vojvodina, Clinic of Dermatovenereology Diseases, Novi Sad, Serbia
3 shared publications - Velibor Čabarkapa
Faculty of Medicine, University of Novi Sad; Center for Laboratory Diagnostics, University Clinical Center of Vojvodina, Novi Sad, Serbia
3 shared publications - Dunja Jakovljevic
Faculty of Pharmacy Novi Sad, 21000 Novi Sad, Serbia
2 shared publications - Jelena Stojcevic-Maletic
Department of Biochemistry, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
2 shared publications - Natasa Vucinic
University of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, Serbia
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Journal of Medical Biochemistry
- Vol. 45 (11) , 2458-2464
Relative BIRC3 gene expression in chronic lymphocytic leukemia
Background: Chronic lymphocytic leukemia (CLL) represents the most frequent type of leukemia in the adult population. It is characterized by highly variable clinical course, predominantly initiated by different genetic alterations responsible for the regulation of cell proliferation and apoptosis. The aim of this study was to evaluate the relative expression of the BIRC3 gene in CLL patients. Methods: This cross-sectional study included 78 participants: a CLL group (n=50) and a control group of healthy subjects (n=28), both ageand sex-matched. To all participants, CBC (complete blood count), basic biochemical parameters, as well as FISH (fluorescent in situ hybridisation) for determining chromosomal aberrations and PCR analyses for determining the relative expression of the BIRC3 (Baculoviral IAP Repeat Containing 3) gene were performed. All reactions were performed on QIA quant 96 5 plex real-time PCR instrument (Qiagen, Hilden, Germany). Additionally, FISH diagnostics was performed using Abbott Vysis CLL FISH Probe Kit (Abbott Molecular diagnostics, Chicago, IL, USA). Results: Deletion of the long arm of the 13th chromosome was the most frequent chromosomal aberration in the CLL group. A statistically significant difference was observed in the relative expression of BIRC3, with higher values in the study group (p=0.019). The results of the binary logistic regression model indicated that lactate dehydrogenase and total calcium were statistically significant predictors of relative BIRC3 gene expression (p < 0.05). Conclusion: Determination of relative BIRC3 gene expression may be a valuable analysis for both the initial diagnosis and the clinical follow-up of CLL patients.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Journal of Medical Biochemistry
- Vol. 45 (11) , 2458-2464
Open AccessRelative BIRC3 gene expression in chronic lymphocytic leukemia
Background: Chronic lymphocytic leukemia (CLL) represents the most frequent type of leukemia in the adult population. It is characterized by highly variable clinical course, predominantly initiated by different genetic alterations responsible for the regulation of cell proliferation and apoptosis. The aim of this study was to evaluate the relative expression of the BIRC3 gene in CLL patients. Methods: This cross-sectional study included 78 participants: a CLL group (n=50) and a control group of healthy subjects (n=28), both ageand sex-matched. To all participants, CBC (complete blood count), basic biochemical parameters, as well as FISH (fluorescent in situ hybridisation) for determining chromosomal aberrations and PCR analyses for determining the relative expression of the BIRC3 (Baculoviral IAP Repeat Containing 3) gene were performed. All reactions were performed on QIA quant 96 5 plex real-time PCR instrument (Qiagen, Hilden, Germany). Additionally, FISH diagnostics was performed using Abbott Vysis CLL FISH Probe Kit (Abbott Molecular diagnostics, Chicago, IL, USA). Results: Deletion of the long arm of the 13th chromosome was the most frequent chromosomal aberration in the CLL group. A statistically significant difference was observed in the relative expression of BIRC3, with higher values in the study group (p=0.019). The results of the binary logistic regression model indicated that lactate dehydrogenase and total calcium were statistically significant predictors of relative BIRC3 gene expression (p < 0.05). Conclusion: Determination of relative BIRC3 gene expression may be a valuable analysis for both the initial diagnosis and the clinical follow-up of CLL patients.
- Open Access
- 1 January 2026
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- No. 00,p. 45
Atopic dermatitis - novel insights in the immunopathology of the disease
Atopic dermatitis is an inflammatory skin disease that is characterized by the chronic-relapsing course and a pronounced feeling of itching. Altered production of structural proteins, lipids and antimicrobial peptides result in the epidermal impairment leading to the early onset of disease, more severe lesions and a numerous comorbidities. Atopic dermatitis has been recently recognized as a systemic type 2 inflammation by which emerging novel therapeutic modalities reflect sophisticated molecular and immunopathological pathways. The aim of this article is to deliver thorough review of the existing knowledge regarding the most significant immunological aspects of the development and progression of atopic dermatitis.
- 1 January 2026
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- No. 00,p. 45
Open AccessAtopic dermatitis - novel insights in the immunopathology of the disease
Atopic dermatitis is an inflammatory skin disease that is characterized by the chronic-relapsing course and a pronounced feeling of itching. Altered production of structural proteins, lipids and antimicrobial peptides result in the epidermal impairment leading to the early onset of disease, more severe lesions and a numerous comorbidities. Atopic dermatitis has been recently recognized as a systemic type 2 inflammation by which emerging novel therapeutic modalities reflect sophisticated molecular and immunopathological pathways. The aim of this article is to deliver thorough review of the existing knowledge regarding the most significant immunological aspects of the development and progression of atopic dermatitis.
- Open Access
- 23 October 2025
- Published by MDPI AG in Clinics and Practice
- Vol. 15 (11) , 192
miRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as Potential Biomarkers for Atopic Dermatitis
Background/Objectives: Recently, epigenetic mechanisms have been recognized as crucial in atopic dermatitis development. The emphasis of this research was on expanding existing knowledge about the epigenetic aspects of atopic dermatitis, as well as identifying new molecules that could serve as disease biomarkers. Methods: The research was conducted as a cross-sectional study examining two groups: the group with atopic dermatitis (50 patients) and the control group (50 healthy adults). The serum levels of total immunoglobulin E (IgE) and eosinophil count (Eos%) were performed in routine laboratory analyses, and the detection of microRNAs from peripheral blood was performed using RT-PCR. Results: Analysis of selected miRNA expressions in patients with atopic dermatitis and controls revealed that only the expression and the relative expression of miRNA-146a were statistically significantly higher in patients with atopic dermatitis than in the control group (p = 0.042 and p = 0.021, respectively). There was a weak positive correlation between miRNA-146a expression and the eosinophilia/IgE level (r = 0.22 and r = 0.25, respectively). MiRNA-21, miRNA-29b, miRNA-143 and miRNA-223 were significantly upregulated in patients with higher SCORAD (p < 0.001, p < 0.001, p < 0.001 and p = 0.015, respectively). ROC curve analysis revealed the specificity of miRNA-146a as 82% and the sensitivity as 62%. The area under the ROC curve (AUC) was 0.7, indicating its diagnostic potential. Conclusions: Our findings imply that miRNA-146a might serve as a biomarker of atopic dermatitis, suggesting its relevance in the development of the disease, while miRNA-21, miRNA-29b, miRNA-143 and miRNA-223 may have an impact on disease progression. Our findings provide a preliminary basis that should precede validation through larger, multicentric studies and use in diagnostics, targeted personalized treatments and monitoring of treatment efficacy in atopic dermatitis.
- 23 October 2025
- Published by MDPI AG in Clinics and Practice
- Vol. 15 (11) , 192
Open AccessmiRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as Potential Biomarkers for Atopic Dermatitis
Background/Objectives: Recently, epigenetic mechanisms have been recognized as crucial in atopic dermatitis development. The emphasis of this research was on expanding existing knowledge about the epigenetic aspects of atopic dermatitis, as well as identifying new molecules that could serve as disease biomarkers. Methods: The research was conducted as a cross-sectional study examining two groups: the group with atopic dermatitis (50 patients) and the control group (50 healthy adults). The serum levels of total immunoglobulin E (IgE) and eosinophil count (Eos%) were performed in routine laboratory analyses, and the detection of microRNAs from peripheral blood was performed using RT-PCR. Results: Analysis of selected miRNA expressions in patients with atopic dermatitis and controls revealed that only the expression and the relative expression of miRNA-146a were statistically significantly higher in patients with atopic dermatitis than in the control group (p = 0.042 and p = 0.021, respectively). There was a weak positive correlation between miRNA-146a expression and the eosinophilia/IgE level (r = 0.22 and r = 0.25, respectively). MiRNA-21, miRNA-29b, miRNA-143 and miRNA-223 were significantly upregulated in patients with higher SCORAD (p < 0.001, p < 0.001, p < 0.001 and p = 0.015, respectively). ROC curve analysis revealed the specificity of miRNA-146a as 82% and the sensitivity as 62%. The area under the ROC curve (AUC) was 0.7, indicating its diagnostic potential. Conclusions: Our findings imply that miRNA-146a might serve as a biomarker of atopic dermatitis, suggesting its relevance in the development of the disease, while miRNA-21, miRNA-29b, miRNA-143 and miRNA-223 may have an impact on disease progression. Our findings provide a preliminary basis that should precede validation through larger, multicentric studies and use in diagnostics, targeted personalized treatments and monitoring of treatment efficacy in atopic dermatitis.
- Open Access
- 17 September 2025
- Published by MDPI AG in Preprints.org
miRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as Potential Biomarkers for Atopic Dermatitis
Background/Objectives: Recently, epigenetic mechanisms have been recognized as crucial in atopic dermatitis development. The emphasis of this research was on ex-panding existing knowledge about the epigenetic aspects of atopic dermatitis, as well as identifying new molecules that could serve as disease biomarkers. Methods: The re-search was conducted as a prospective study examining two groups: the group with atopic dermatitis (50 patients) and the control group (50 healthy adults). The serum levels of total immunoglobulin E (IgE) and eosinophil count (Eos%) were done in rou-tine laboratory analyses, and the detection of microRNAs from peripheral blood was performed using RT-PCR. Results: Analysis of selected miRNA expression in patients with atopic dermatitis and controls revealed that only the expression and the relative expression of miRNA-146a were statistically significantly higher in patients with atopic dermatitis than in the control group (p=0.042 and p=0.021, respectively). There was a weak positive correlation between miRNA-146a expression and the eosinophilia / IgE level (r=0.22 and r=0.25, respectively). The miRNA-21, miRNA-29b, miRNA-143 and miRNA-223 were significantly upregulated in patients with higher SCORAD (p< 0.001, p< 0.001, p< 0.001 and p= 0.015, respectively). ROC curve analysis revealed the specificity of miRNA-146a as 82% and the sensitivity as 62%. The area under the ROC curve (AUC) was 0.7, confirming a valid diagnostic potential. Conclusions: Our find-ings imply that miRNA-146a may be a novel biomarker of atopic dermatitis and might play a specific role in the development of the disease, while miRNA-21, miRNA-29b and miRNA-223 may have an impact on the disease progression. Our study provides findings that can be utilized in future diagnostic applications, targeted personalized treatments and support the monitoring of atopic dermatitis treatment effectiveness.
- 17 September 2025
- Published by MDPI AG in Preprints.org
Open AccessmiRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as Potential Biomarkers for Atopic Dermatitis
Background/Objectives: Recently, epigenetic mechanisms have been recognized as crucial in atopic dermatitis development. The emphasis of this research was on ex-panding existing knowledge about the epigenetic aspects of atopic dermatitis, as well as identifying new molecules that could serve as disease biomarkers. Methods: The re-search was conducted as a prospective study examining two groups: the group with atopic dermatitis (50 patients) and the control group (50 healthy adults). The serum levels of total immunoglobulin E (IgE) and eosinophil count (Eos%) were done in rou-tine laboratory analyses, and the detection of microRNAs from peripheral blood was performed using RT-PCR. Results: Analysis of selected miRNA expression in patients with atopic dermatitis and controls revealed that only the expression and the relative expression of miRNA-146a were statistically significantly higher in patients with atopic dermatitis than in the control group (p=0.042 and p=0.021, respectively). There was a weak positive correlation between miRNA-146a expression and the eosinophilia / IgE level (r=0.22 and r=0.25, respectively). The miRNA-21, miRNA-29b, miRNA-143 and miRNA-223 were significantly upregulated in patients with higher SCORAD (p< 0.001, p< 0.001, p< 0.001 and p= 0.015, respectively). ROC curve analysis revealed the specificity of miRNA-146a as 82% and the sensitivity as 62%. The area under the ROC curve (AUC) was 0.7, confirming a valid diagnostic potential. Conclusions: Our find-ings imply that miRNA-146a may be a novel biomarker of atopic dermatitis and might play a specific role in the development of the disease, while miRNA-21, miRNA-29b and miRNA-223 may have an impact on the disease progression. Our study provides findings that can be utilized in future diagnostic applications, targeted personalized treatments and support the monitoring of atopic dermatitis treatment effectiveness.
- 12 December 2024
- Published by Springer Nature
- p. 177-188
Adipose Tissue Angiogenesis and Clinical Implications
- 12 December 2024
- Published by Springer Nature
- p. 177-188
Adipose Tissue Angiogenesis and Clinical Implications
- Open Access
- 1 January 2024
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 77 (5-6) , 160-164
Association between inherited thrombophilia and ischemic brain disease in Vojvodina
Introduction. The most common genetic causes of thrombophilia include deficiency of histidine-rich glycoprotein, proteins C and S, antithrombin III, as well as mutations in the factor V and factor II genes. Thrombophilia is primarily associated with an elevated risk of deep vein thrombosis and/or thromboembolism; however, thrombosis can also occur in atypical locations such as the retinal, cerebral, and splanchnic veins. Ischemic stroke can result from restricted blood flow to the brain. Some studies suggest a potential link between ischemic brain disease and inherited thrombophilia. Material and Methods. Venous blood samples were used to extract genomic DNA, and detection of allele types in patients and controls was performed using realtime polymerase chain reaction on Gentier 96R Real-Time PCR System (TianLong, China) with an allelic discrimination assay. Results. Among the risk factors evaluated, the most common one linked to the development of cerebral ischemia was resistance to activated protein C due to the presence of FV Leiden mutation. Conclusion. Further studies involving larger cohorts of patients with reported cases of cerebral ischemia are necessary to determine whether a significant association exists between inherited thrombophilia and cerebral ischemia.
- 1 January 2024
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 77 (5-6) , 160-164
Open AccessAssociation between inherited thrombophilia and ischemic brain disease in Vojvodina
Introduction. The most common genetic causes of thrombophilia include deficiency of histidine-rich glycoprotein, proteins C and S, antithrombin III, as well as mutations in the factor V and factor II genes. Thrombophilia is primarily associated with an elevated risk of deep vein thrombosis and/or thromboembolism; however, thrombosis can also occur in atypical locations such as the retinal, cerebral, and splanchnic veins. Ischemic stroke can result from restricted blood flow to the brain. Some studies suggest a potential link between ischemic brain disease and inherited thrombophilia. Material and Methods. Venous blood samples were used to extract genomic DNA, and detection of allele types in patients and controls was performed using realtime polymerase chain reaction on Gentier 96R Real-Time PCR System (TianLong, China) with an allelic discrimination assay. Results. Among the risk factors evaluated, the most common one linked to the development of cerebral ischemia was resistance to activated protein C due to the presence of FV Leiden mutation. Conclusion. Further studies involving larger cohorts of patients with reported cases of cerebral ischemia are necessary to determine whether a significant association exists between inherited thrombophilia and cerebral ischemia.
- Open Access
- 1 January 2023
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (00) , 74
Comparison of diagnostic efficacy of the Abbott RealTime SARS-CoV-2 assay and the BGI real-time fluorescent RT-PCR kit for the RT-PCR-based detection of Severe Acute Respiratory Syndrome Coronavirus-2
Introduction/Objective. Based on the World Health Organization guidelines, the current "gold standard" to diagnose Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR). The objective of this study was to compare and analyze the detection performance of two different authorized SARS-CoV-2 nucleic acid detection assays: the Abbott RealTime SARS-CoV-2 (ACOV) assay and the BGI Real-Time Fluorescent RT-PCR (BGI) kit. Methods. Our study included 384 randomly selected nasopharyngeal and oropharyngeal swabs previously tested by the ACOV and subsequently tested by the BGI kit for detecting SARS-CoV-2. All patients were adult individuals with symptoms or suspected of Coronavirus disease 2019 (COVID-19). Results. We found that the ACOV assay detected more cases of COVID-19 infection than the BGI assay. The positive percent agreement was 98.3% (95% confidence intervals (95% CI): 95.7-99.3%), while Cohen’s Kappa coefficient (Kappa) was 0.86 (95% CI: 0.80-0.91), indicating a strong level of agreement between these two tests. The negative percent agreement was 85.1% (95% CI: 78.3-90%), while 5.47% of cases were false negative using the BGI test to detect SARS-CoV-2. The sensitivity of the BGI test compared to Abbott was 91.73% (95% CI: 87.64-94.81%), and the specificity of the BGI test was 96.77% (95% CI: 91.95-99.11%). Conclusion. The Abbott kit showed a bit better diagnostic performance, and due to possible false negative results using the BGI test, we recommend complete testing with the ACOV test.
- 1 January 2023
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (00) , 74
Open AccessComparison of diagnostic efficacy of the Abbott RealTime SARS-CoV-2 assay and the BGI real-time fluorescent RT-PCR kit for the RT-PCR-based detection of Severe Acute Respiratory Syndrome Coronavirus-2
Introduction/Objective. Based on the World Health Organization guidelines, the current "gold standard" to diagnose Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR). The objective of this study was to compare and analyze the detection performance of two different authorized SARS-CoV-2 nucleic acid detection assays: the Abbott RealTime SARS-CoV-2 (ACOV) assay and the BGI Real-Time Fluorescent RT-PCR (BGI) kit. Methods. Our study included 384 randomly selected nasopharyngeal and oropharyngeal swabs previously tested by the ACOV and subsequently tested by the BGI kit for detecting SARS-CoV-2. All patients were adult individuals with symptoms or suspected of Coronavirus disease 2019 (COVID-19). Results. We found that the ACOV assay detected more cases of COVID-19 infection than the BGI assay. The positive percent agreement was 98.3% (95% confidence intervals (95% CI): 95.7-99.3%), while Cohen’s Kappa coefficient (Kappa) was 0.86 (95% CI: 0.80-0.91), indicating a strong level of agreement between these two tests. The negative percent agreement was 85.1% (95% CI: 78.3-90%), while 5.47% of cases were false negative using the BGI test to detect SARS-CoV-2. The sensitivity of the BGI test compared to Abbott was 91.73% (95% CI: 87.64-94.81%), and the specificity of the BGI test was 96.77% (95% CI: 91.95-99.11%). Conclusion. The Abbott kit showed a bit better diagnostic performance, and due to possible false negative results using the BGI test, we recommend complete testing with the ACOV test.
- Open Access
- 1 January 2023
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (9-10) , 572-577
Impact of epidermal growth factor receptor gene RS1468727 polymorphism on survival of the patients with oral squamous cell carcinoma
Introduction/Objective. Genetic aberrations and environmental factors are known to play an important role in oral squamous cell carcinoma (OSCC). The aim of the study was to clarify the association of epidermal growth factor receptor (EGFR) gene polymorphism rs1468727 with overall survival (OS) in patients with OSCC. Methods. The study comprised a total of sixty-one patients diagnosed with OSCC. The follow-up period for each patient was 3 years from the date of surgery and during that period their genotypes for rs1468727 polymorphism of the EGFR gene were identified using Real-Time PCR. Binary logistic regression was used to investigate the influence of various variables on survival. Additionally, the Chi-square test of independence and Man-Whitney U test were done to examine the interplay between two categorical variables and two independent samples. Results. Two variables demonstrated a statistically significant influence on OS: the TNM Classification (TNM) stage and EGFR genotype. At the end of the follow-up period, 39 patients survived, with a noteworthy observation that more than half of the survivors had the EGFR rs1468727 CC genotype. The distribution of CC and CT genotypes was equal (chi-square = 0.397, df = 2 p = 0.820) among patients who deceased indicating that no statistically significant correlations were found between OS and demographic or tumor-related characteristics. Conclusion. EGFR rs1468727 homozygote (genotype CC) and TNM stage showed statistically significant influence on OS in the follow-up period. This study highlights the potential significance of homozygote EGFR rs1468727 CC in assessing the prognosis and treatment outcomes of patients undergoing surgery for OSCC.
- 1 January 2023
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (9-10) , 572-577
Open AccessImpact of epidermal growth factor receptor gene RS1468727 polymorphism on survival of the patients with oral squamous cell carcinoma
Introduction/Objective. Genetic aberrations and environmental factors are known to play an important role in oral squamous cell carcinoma (OSCC). The aim of the study was to clarify the association of epidermal growth factor receptor (EGFR) gene polymorphism rs1468727 with overall survival (OS) in patients with OSCC. Methods. The study comprised a total of sixty-one patients diagnosed with OSCC. The follow-up period for each patient was 3 years from the date of surgery and during that period their genotypes for rs1468727 polymorphism of the EGFR gene were identified using Real-Time PCR. Binary logistic regression was used to investigate the influence of various variables on survival. Additionally, the Chi-square test of independence and Man-Whitney U test were done to examine the interplay between two categorical variables and two independent samples. Results. Two variables demonstrated a statistically significant influence on OS: the TNM Classification (TNM) stage and EGFR genotype. At the end of the follow-up period, 39 patients survived, with a noteworthy observation that more than half of the survivors had the EGFR rs1468727 CC genotype. The distribution of CC and CT genotypes was equal (chi-square = 0.397, df = 2 p = 0.820) among patients who deceased indicating that no statistically significant correlations were found between OS and demographic or tumor-related characteristics. Conclusion. EGFR rs1468727 homozygote (genotype CC) and TNM stage showed statistically significant influence on OS in the follow-up period. This study highlights the potential significance of homozygote EGFR rs1468727 CC in assessing the prognosis and treatment outcomes of patients undergoing surgery for OSCC.
- 1 January 2023
- Published by Taylor & Francis in Future Virology
- Vol. 18 (1) , 31-38
Diagnosing COVID-19: diagnostic importance of detectingEgene of the SARS-CoV-2 genome
Aim: To evaluate the significance of E gene analysis in addition to N and RdRp genes of SARS-CoV-2, and to compare the specificity and sensitivity of targets. Materials & methods: We used two reverse transcription-PCR assays: one targeting N, E and RdRp and the other targeting N and RdRp genes and analyzed variation in threshold cycle (Ct) values. Results: Of the 155 samples, 70.32% tested positive: all three genes were detected in 45.87%, N and RdRp in 19.27% and only N in 34.86%. Patients negative for the E gene were tested after symptoms disappeared and Ct values were significantly higher. Conclusion: Samples negative for the E gene were potentially false positive and clinical conditions should be assessed while interpreting results.
- 1 January 2023
- Published by Taylor & Francis in Future Virology
- Vol. 18 (1) , 31-38
Diagnosing COVID-19: diagnostic importance of detectingEgene of the SARS-CoV-2 genome
Aim: To evaluate the significance of E gene analysis in addition to N and RdRp genes of SARS-CoV-2, and to compare the specificity and sensitivity of targets. Materials & methods: We used two reverse transcription-PCR assays: one targeting N, E and RdRp and the other targeting N and RdRp genes and analyzed variation in threshold cycle (Ct) values. Results: Of the 155 samples, 70.32% tested positive: all three genes were detected in 45.87%, N and RdRp in 19.27% and only N in 34.86%. Patients negative for the E gene were tested after symptoms disappeared and Ct values were significantly higher. Conclusion: Samples negative for the E gene were potentially false positive and clinical conditions should be assessed while interpreting results.
- Open Access
- 1 January 2022
- Published by National Library of Serbia in Genetika
- Vol. 54 (1) , 427-438
Comparison of abbott Real Time SARS-COV-2 ASSAY, Genefinder™ Covid-19 plus realamp kit and Biomerieux Argene® SARS-COV-2 R-Gene® kit for the RT-PCR based detection of SARS-COV-2 from nasopharyngeal swabs
Early, rapid and reliable identification of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is crucial for successful control of coronavirus disease 2019 (COVID-19). The quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) assay is considered the gold standard for molecular diagnosis of SARS-CoV-2. The objective of this study was to compare the clinical performances of the three authorized tests - the Abbott Real Time SARS-CoV-2 (ACOV) assay (Abbott Molecular Inc., North Chicago, IL), GeneFinder™ COVID-19 Plus RealAmp (GeneFinder) Kit (OSANG Healthcare Co., Ltd, Dongan-gu Anyang, Korea) and the Biomerieux ARGENE® SARS-COV-2 R-GENE® real-time detection (ARGENE) kit (bioMérieux SA., Marcyl’Étoile, France) and to determine whether the selection of targeted genes has an impact on test's specificity. In this study, we included 155 nasopharyngeal swabs (NPS) from adult individuals with symptoms or suspected of COVID-19, aged from 17 to 91 years, previously tested by the ACOV and subsequently tested by the GeneFinder and the ARGENE. In this comparative analysis, we found that the GeneFinder assay detected the most cases of COVID-19 infection, followed by the ACOV assay, and then by ARGENE. Positive agreement ranged from 74.74% to 95.41%, with the strongest agreement observed between the GeneFinder and ACOV assays - 95.41% (95% confidence intervals (CI): 89.37%-98.36%) indicating an excellent agreement between these two tests and the lowest agreement between the GeneFinder and ARGENE assay - 74.74% (95% CI: 65.08%-81.41%). The negative percent agreement was 100% (GeneFinder/ACOV, GeneFinder/ARGENE and ACOV/ARGENE). Only 3.2% of cases were false-negative using the ACOV test, while 18.0% of samples were false-negative using the ARGENE assay to detect SARS-CoV-2. Combined usage of the Abbott SARS-CoV-2 and the GeneFinder assays can be applied to maximize SARS-CoV-2 detection accuracy.
- 1 January 2022
- Published by National Library of Serbia in Genetika
- Vol. 54 (1) , 427-438
Open AccessComparison of abbott Real Time SARS-COV-2 ASSAY, Genefinder™ Covid-19 plus realamp kit and Biomerieux Argene® SARS-COV-2 R-Gene® kit for the RT-PCR based detection of SARS-COV-2 from nasopharyngeal swabs
Early, rapid and reliable identification of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is crucial for successful control of coronavirus disease 2019 (COVID-19). The quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) assay is considered the gold standard for molecular diagnosis of SARS-CoV-2. The objective of this study was to compare the clinical performances of the three authorized tests - the Abbott Real Time SARS-CoV-2 (ACOV) assay (Abbott Molecular Inc., North Chicago, IL), GeneFinder™ COVID-19 Plus RealAmp (GeneFinder) Kit (OSANG Healthcare Co., Ltd, Dongan-gu Anyang, Korea) and the Biomerieux ARGENE® SARS-COV-2 R-GENE® real-time detection (ARGENE) kit (bioMérieux SA., Marcyl’Étoile, France) and to determine whether the selection of targeted genes has an impact on test's specificity. In this study, we included 155 nasopharyngeal swabs (NPS) from adult individuals with symptoms or suspected of COVID-19, aged from 17 to 91 years, previously tested by the ACOV and subsequently tested by the GeneFinder and the ARGENE. In this comparative analysis, we found that the GeneFinder assay detected the most cases of COVID-19 infection, followed by the ACOV assay, and then by ARGENE. Positive agreement ranged from 74.74% to 95.41%, with the strongest agreement observed between the GeneFinder and ACOV assays - 95.41% (95% confidence intervals (CI): 89.37%-98.36%) indicating an excellent agreement between these two tests and the lowest agreement between the GeneFinder and ARGENE assay - 74.74% (95% CI: 65.08%-81.41%). The negative percent agreement was 100% (GeneFinder/ACOV, GeneFinder/ARGENE and ACOV/ARGENE). Only 3.2% of cases were false-negative using the ACOV test, while 18.0% of samples were false-negative using the ARGENE assay to detect SARS-CoV-2. Combined usage of the Abbott SARS-CoV-2 and the GeneFinder assays can be applied to maximize SARS-CoV-2 detection accuracy.